SpyGlass Pharma, Inc. (SGP) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-1.34x
SpyGlass Pharma, Inc. (SGP) has a Cash Flow-to-Debt Ratio of -1.34x as of June 2026, meaning its operating cash flow of $-14.84 Million could theoretically repay -1% of its total liabilities ($11.07 Million) in one year. See SpyGlass Pharma, Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.34x
Operating CF / Total Liabilities
Operating Cash Flow
$-14.84 Million
USD
Total Liabilities
$11.07 Million
USD
Data as of
Jun 2026
Most recent filing
SpyGlass Pharma, Inc. Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for SpyGlass Pharma, Inc. across 3 annual periods. For the full cash flow conversion analysis, see SGP cash flow conversion.
Annual Cash Flow-to-Debt Ratio for SpyGlass Pharma, Inc. (2023–2025)
Year-by-year debt coverage analysis for SpyGlass Pharma, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.15x | $-32.70 Million | $214.70 Million | ▲ +42.1% |
| 2024 | -0.26x | $-22.03 Million | $83.79 Million | ▼ -58.7% |
| 2023 | -0.17x | $-12.28 Million | $74.13 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.